Predictors of orphan drug approval
نویسندگان
چکیده
منابع مشابه
Predictors of orphan drug approval
Results More orphan drugs were developed in the US during the first ten years of the US Orphan Drug Act (1983-1992, N=73) and during the first ten years of the EU Regulation on Orphan Medicinal products (2000-2009, N=112) than in the EU (2000-2009, N=59). Orphan drug approval was strongly associated with previous experiences of the sponsor in obtaining approval for another orphan drug (OR=17.3,...
متن کاملLeveraging existing opportunities for improved Orphan Drug approval in the EU
The EU regulatory framework provides opportunities for increased flexibility and speed for Orphan Medicinal Product (OMP) marketing authorisations. Nevertheless the yearly rate of OMP approvals is not increasing [1] and available tools and procedures are used infrequently. According to a review of approval timelines from 20012010 [2], FDA median total review time for OMPs (235 days) was almost ...
متن کاملDrug approval and drug effectiveness.
Data on the efficacy and safety of psychiatric medicines should form the foundation of evidence-based treatment practices. The US Food and Drug Administration (FDA) reviews such data in determining whether to approve new treatments, and the published literature serves as a repository for evidence on treatment benefits and harms. We describe the FDA review of clinical trials, examining the under...
متن کاملMethadone: An Orphan Drug?
73 Dear Editor: A pharmaceutical product is called “orphan drug” when, although promising or clearly valid from a scientific and therapeutic point of view, it is not profit-bearing and, therefore, not interesting for the pharmaceutical industry. The consequences are the lack of extensive research on its effects, and mainly, the lack of appropriate information to physicians, nurses, and administ...
متن کاملFDA drug approval summaries: oxaliplatin.
The purpose of this report is to summarize information on oxaliplatin, a drug recently approved by the U.S. Food and Drug Administration. Information provided includes regulatory history, study design, efficacy and safety results, and pertinent literature references. A single, multicenter, randomized trial, enrolling 463 patients with metastatic colorectal carcinoma whose disease had recurred o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Orphanet Journal of Rare Diseases
سال: 2010
ISSN: 1750-1172
DOI: 10.1186/1750-1172-5-s1-o18